---
document_datetime: 2025-12-02 05:12:43
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/kromeya.html
document_name: kromeya.html
version: success
processing_time: 0.1118812
conversion_datetime: 2025-12-27 20:28:35.848495
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Kromeya

[RSS](/en/individual-human-medicine.xml/67188)

##### Withdrawn

This medicine's authorisation has been withdrawn

adalimumab Medicine Human Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Kromeya](#news-on)
- [Related content](#related-content-891)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 17 December 2019, the European Commission withdrew the marketing authorisation for Kromeya (adalimumab) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Fresenius Kabi Deutschland GmbH, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Kromeya was granted marketing authorisation in the EU on 2 April 2019 for the treatment of plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, juvenile idiopathic arthritis, Crohn's disease, ulcerative colitis and non-infectious uveitis. The marketing authorisation was initially valid for a 5-year period. The product had never been marketed in the EU.

Kromeya is a biosimilar of Humira. There are other biosimilar medicinal products of Humira authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Kromeya is updated to indicate that the marketing authorisation is no longer valid.

Kromeya : EPAR - Medicine overview

Reference Number: EMA/591446/2019

English (EN) (730.29 KB - PDF)

**First published:** 26/04/2019

**Last updated:** 24/03/2020

[View](/en/documents/overview/kromeya-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-108)

български (BG) (821.53 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/bg/documents/overview/kromeya-epar-medicine-overview_bg.pdf)

español (ES) (730.26 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/es/documents/overview/kromeya-epar-medicine-overview_es.pdf)

čeština (CS) (804.76 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/cs/documents/overview/kromeya-epar-medicine-overview_cs.pdf)

dansk (DA) (728.3 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/da/documents/overview/kromeya-epar-medicine-overview_da.pdf)

Deutsch (DE) (738.7 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/de/documents/overview/kromeya-epar-medicine-overview_de.pdf)

eesti keel (ET) (715.45 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/et/documents/overview/kromeya-epar-medicine-overview_et.pdf)

ελληνικά (EL) (849.97 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/el/documents/overview/kromeya-epar-medicine-overview_el.pdf)

français (FR) (736.43 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/fr/documents/overview/kromeya-epar-medicine-overview_fr.pdf)

hrvatski (HR) (753.38 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/hr/documents/overview/kromeya-epar-medicine-overview_hr.pdf)

italiano (IT) (727.5 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/it/documents/overview/kromeya-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (813.57 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/lv/documents/overview/kromeya-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (754.24 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/lt/documents/overview/kromeya-epar-medicine-overview_lt.pdf)

magyar (HU) (819.58 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/hu/documents/overview/kromeya-epar-medicine-overview_hu.pdf)

Malti (MT) (807.88 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/mt/documents/overview/kromeya-epar-medicine-overview_mt.pdf)

Nederlands (NL) (733.48 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/nl/documents/overview/kromeya-epar-medicine-overview_nl.pdf)

polski (PL) (822.38 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/pl/documents/overview/kromeya-epar-medicine-overview_pl.pdf)

português (PT) (730.73 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/pt/documents/overview/kromeya-epar-medicine-overview_pt.pdf)

română (RO) (1.32 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/ro/documents/overview/kromeya-epar-medicine-overview_ro.pdf)

slovenčina (SK) (805.04 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/sk/documents/overview/kromeya-epar-medicine-overview_sk.pdf)

slovenščina (SL) (828.67 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/sl/documents/overview/kromeya-epar-medicine-overview_sl.pdf)

Suomi (FI) (725.33 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/fi/documents/overview/kromeya-epar-medicine-overview_fi.pdf)

svenska (SV) (727.14 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

24/03/2020

[View](/sv/documents/overview/kromeya-epar-medicine-overview_sv.pdf)

Kromeya : EPAR - Risk-management-plan summary

English (EN) (892.53 KB - PDF)

**First published:** 26/04/2019

[View](/en/documents/rmp-summary/kromeya-epar-risk-management-plan-summary_en.pdf)

## Product information

Kromeya : EPAR - Product information

English (EN) (6.15 MB - PDF)

**First published:** 26/04/2019

**Last updated:** 23/10/2019

[View](/en/documents/product-information/kromeya-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-718)

български (BG) (11.03 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/bg/documents/product-information/kromeya-epar-product-information_bg.pdf)

español (ES) (6.64 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/es/documents/product-information/kromeya-epar-product-information_es.pdf)

čeština (CS) (8.55 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/cs/documents/product-information/kromeya-epar-product-information_cs.pdf)

dansk (DA) (3.51 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/da/documents/product-information/kromeya-epar-product-information_da.pdf)

Deutsch (DE) (8.68 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/de/documents/product-information/kromeya-epar-product-information_de.pdf)

eesti keel (ET) (5.79 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/et/documents/product-information/kromeya-epar-product-information_et.pdf)

ελληνικά (EL) (11.4 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/el/documents/product-information/kromeya-epar-product-information_el.pdf)

français (FR) (3.76 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/fr/documents/product-information/kromeya-epar-product-information_fr.pdf)

hrvatski (HR) (6.46 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/hr/documents/product-information/kromeya-epar-product-information_hr.pdf)

íslenska (IS) (6.28 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/is/documents/product-information/kromeya-epar-product-information_is.pdf)

italiano (IT) (6.68 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/it/documents/product-information/kromeya-epar-product-information_it.pdf)

latviešu valoda (LV) (9.21 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/lv/documents/product-information/kromeya-epar-product-information_lv.pdf)

lietuvių kalba (LT) (6.49 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/lt/documents/product-information/kromeya-epar-product-information_lt.pdf)

magyar (HU) (17.82 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/hu/documents/product-information/kromeya-epar-product-information_hu.pdf)

Malti (MT) (10.16 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/mt/documents/product-information/kromeya-epar-product-information_mt.pdf)

Nederlands (NL) (6.49 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/nl/documents/product-information/kromeya-epar-product-information_nl.pdf)

norsk (NO) (4.48 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/no/documents/product-information/kromeya-epar-product-information_no.pdf)

polski (PL) (9.76 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/pl/documents/product-information/kromeya-epar-product-information_pl.pdf)

português (PT) (6.04 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/pt/documents/product-information/kromeya-epar-product-information_pt.pdf)

română (RO) (7.98 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/ro/documents/product-information/kromeya-epar-product-information_ro.pdf)

slovenčina (SK) (9.52 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/sk/documents/product-information/kromeya-epar-product-information_sk.pdf)

slovenščina (SL) (9.1 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/sl/documents/product-information/kromeya-epar-product-information_sl.pdf)

Suomi (FI) (4.66 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/fi/documents/product-information/kromeya-epar-product-information_fi.pdf)

svenska (SV) (6.06 MB - PDF)

**First published:**

26/04/2019

**Last updated:**

23/10/2019

[View](/sv/documents/product-information/kromeya-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** WS/1651 03/10/2019

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Kromeya : EPAR - All authorised presentations

English (EN) (626.01 KB - PDF)

**First published:** 26/04/2019

**Last updated:** 03/10/2019

[View](/en/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-929)

български (BG) (678.4 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/bg/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_bg.pdf)

español (ES) (619.08 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/es/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_es.pdf)

čeština (CS) (692.62 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/cs/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (583.6 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/da/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (679.09 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/de/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (686.2 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/et/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (686.37 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/el/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_el.pdf)

français (FR) (583.56 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/fr/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (668.79 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/hr/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (636.03 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/is/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_is.pdf)

italiano (IT) (584.03 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/it/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (715.37 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/lv/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (707.32 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/lt/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (760.54 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/hu/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (763.13 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/mt/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (616.62 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/nl/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (617.91 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/no/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_no.pdf)

polski (PL) (667.6 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/pl/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_pl.pdf)

português (PT) (609.16 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/pt/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_pt.pdf)

română (RO) (646.27 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/ro/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (706.78 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/sk/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (738.06 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/sl/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (584.57 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/fi/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (639.78 KB - PDF)

**First published:**

26/04/2019

**Last updated:**

03/10/2019

[View](/sv/documents/all-authorised-presentations/kromeya-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Kromeya Active substance adalimumab International non-proprietary name (INN) or common name adalimumab Therapeutic area (MeSH)

- Arthritis, Rheumatoid
- Arthritis, Juvenile Rheumatoid
- Psoriasis
- Arthritis, Psoriatic
- Spondylitis, Ankylosing
- Uveitis
- Colitis, Ulcerative
- Crohn Disease

Anatomical therapeutic chemical (ATC) code L04AB04

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

**Rheumatoid arthritis**

Kromeya in combination with methotrexate, is indicated for:

- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.
- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.

Kromeya can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.

Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.

**Juvenile idiopathic arthritis**

*Polyarticular juvenile idiopathic arthritis*

Kromeya in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Idacio can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.

*Enthesitis-related arthritis*

Kromeya is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).

**Axial spondyloarthritis**

*Ankylosing spondylitis (AS)*

Kromeya is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.

*Axial spondyloarthritis without radiographic evidence of AS*

Kromeya is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs.

**Psoriatic arthritis**

Kromeya is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.

Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.

**Psoriasis**

Kromeya is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.

**Paediatric plaque psoriasis**

Kromeya is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.

**Crohn's disease**

Kromeya is indicated for treatment of moderately to severely active Crohn's disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.

**Paediatric Crohn's disease**

Kromeya is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.

**Ulcerative colitis**

Kromeya is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

**Uveitis**

Kromeya is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.

**Paediatric Uveitis**

Kromeya is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

## Authorisation details

EMA product number EMEA/H/C/005158

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Fresenius Kabi Deutschland GmbH

Else-Kröner-Straße 1,

Opinion adopted 31/01/2019 Marketing authorisation issued 02/04/2019 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Kromeya : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (652.14 KB - PDF)

**First published:** 29/07/2019

**Last updated:** 23/10/2019

[View](/en/documents/procedural-steps-after/kromeya-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Kromeya : EPAR - Public assessment report

Adopted

Reference Number: EMA/214726/2019

English (EN) (3.9 MB - PDF)

**First published:** 26/04/2019

[View](/en/documents/assessment-report/kromeya-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Kromeya

Adopted

Reference Number: EMA/CHMP/45722/2019

English (EN) (701.3 KB - PDF)

**First published:** 31/01/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-kromeya_en.pdf)

#### News on Kromeya

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019) 01/02/2019

#### Related content

- [Biosimilar medicines: Overview](/en/human-regulatory-overview/biosimilar-medicines-overview)

**This page was last updated on** 25/03/2020

## Share this page

[Back to top](#main-content)